# Study of Epratuzumab in Systemic Lupus Erythematosus

> **NCT00111306** · PHASE3 · TERMINATED · sponsor: **UCB Pharma** · enrollment: 510 (—)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** epratuzumab

## Key facts

- **NCT ID:** NCT00111306
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-06
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 510 (—)
- **Last updated:** 2011-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00111306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00111306, "Study of Epratuzumab in Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00111306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*